USPTO Patent Grant: Light-Emitting Element with Long Lifetime

The USPTO has granted a patent (US12588408B2) to Semiconductor Energy Laboratory Co., Ltd. for a novel light-emitting element. The patent describes an element with a long lifetime and high efficiency, utilizing specific organic acceptor and host materials in its electron-transport layers.

USPTO Patent Grant for PCSK9 Inhibitors

The USPTO has granted a patent (US12584120B2) to AstraZeneca AB for novel PCSK9 inhibitors and methods of use. The patent covers specific heteroaryl compounds that bind the PCSK9 protein, aiming to advance treatments for conditions related to cholesterol regulation.

USPTO Patent Grant: PSMA Imaging Agents

The United States Patent and Trademark Office (USPTO) has granted patent US12583887B2 to Siemens Medical Solutions USA, Inc. for PSMA imaging agents. The patent covers compounds and methods for imaging prostate-specific membrane antigen (PSMA), suitable for PET and SPECT imaging.

USPTO Grants PRMT5 Inhibitors Patent to Merck Sharp & Dohme

The USPTO has granted a new patent (US12583871B2) to Merck Sharp & Dohme LLC for PRMT5 inhibitors. The patent covers compounds and methods for treating conditions such as cancer, sickle cell, and hereditary persistence of foetal hemoglobin.

Azaheteroaryl Compound Patent Granted

The USPTO has granted patent US12583870B2 to SHANGHAI BLUERAY BIOPHARMA CO., LTD. for an azaheteroaryl compound and its preparation method. This patent covers compounds and compositions for treating diseases related to EED protein and PRC2 protein complex mechanisms.

A2A Receptor Antagonist Salt and Crystal Forms

The USPTO has granted patent US12583869B2 for a salt form and crystal form of an adenosine A2A receptor antagonist, along with its preparation method. The patent, assigned to CSTONE PHARMACEUTICAL (SUZHOU) CO., LTD., also covers the application of these forms in preparing medicine for A2A receptor-related diseases.

USPTO Patent Grant: JAK Inhibitors Synthesis Methods

The USPTO has granted patent US12583868B2 for novel JAK inhibitors and methods for their synthesis and use, assigned to Galderma Holding SA. The patent covers compounds with formula (I) and their application in treating various diseases.

USPTO Patent Grant: Pyridone Derivative Crystal Form

The USPTO has granted a patent to Jiangxi Caishi Pharmaceutical Technology Co., Ltd. for a novel pyridone derivative crystal form and its preparation method. This patent covers specific crystal forms and their application in treating influenza, potentially offering improved efficacy and bioavailability.

USPTO Patent Grant: IAP Antagonists for Cancer Treatment

The USPTO has granted a patent (US12583866B2) to BeOne Medicines I GmbH for novel pyrido[2,3-b][1,4]oxazine or tetrahydropyrido[2,3-b][1,4]oxazepine derivatives. These compounds act as antagonists of Inhibitors of Apoptosis Proteins (IAPs) and are intended for use in treating cancer by inducing or sensitizing cells to apoptotic cell death.

Biologically Active Taxane Analogs and Oral Treatment Methods - Patent Granted

The USPTO has granted a patent (US12583865B2) to Tapestry Pharmaceuticals, Inc. for biologically active taxane analogs and methods of oral treatment for cancer. The patent covers novel chemical compounds, compositions, manufacturing methods, and combinations with other therapeutic agents.